HUE054009T2 - Szubsztituált tetrahidrokinolinon vegyületek ROR gamma modulátorként - Google Patents

Szubsztituált tetrahidrokinolinon vegyületek ROR gamma modulátorként

Info

Publication number
HUE054009T2
HUE054009T2 HUE16795974A HUE16795974A HUE054009T2 HU E054009 T2 HUE054009 T2 HU E054009T2 HU E16795974 A HUE16795974 A HU E16795974A HU E16795974 A HUE16795974 A HU E16795974A HU E054009 T2 HUE054009 T2 HU E054009T2
Authority
HU
Hungary
Prior art keywords
ror gamma
gamma modulators
compounds
substituted tetrahydroquinolinone
substituted
Prior art date
Application number
HUE16795974A
Other languages
English (en)
Inventor
Ujjinamatada Ravi Kotrabasaiah
Chetan Pandit
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of HUE054009T4 publication Critical patent/HUE054009T4/hu
Publication of HUE054009T2 publication Critical patent/HUE054009T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE16795974A 2015-05-15 2016-05-13 Szubsztituált tetrahidrokinolinon vegyületek ROR gamma modulátorként HUE054009T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2448CH2015 2015-05-15

Publications (2)

Publication Number Publication Date
HUE054009T4 HUE054009T4 (hu) 2021-06-28
HUE054009T2 true HUE054009T2 (hu) 2021-08-30

Family

ID=57319522

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE16795974A HUE054009T2 (hu) 2015-05-15 2016-05-13 Szubsztituált tetrahidrokinolinon vegyületek ROR gamma modulátorként

Country Status (26)

Country Link
US (3) US20180200247A1 (hu)
EP (2) EP3845526A1 (hu)
JP (2) JP6684516B2 (hu)
KR (1) KR102702236B1 (hu)
CN (2) CN113121497A (hu)
AU (2) AU2016262969C1 (hu)
BR (1) BR112017024517A2 (hu)
CA (1) CA2985547C (hu)
CU (1) CU24487B1 (hu)
CY (1) CY1124129T1 (hu)
DK (1) DK3294713T5 (hu)
EA (1) EA036679B1 (hu)
ES (1) ES2868175T3 (hu)
HK (1) HK1255229A1 (hu)
HR (1) HRP20210745T1 (hu)
HU (1) HUE054009T2 (hu)
IL (2) IL255522B (hu)
LT (1) LT3294713T (hu)
MX (2) MX2021009561A (hu)
MY (1) MY189194A (hu)
PH (1) PH12017502052A1 (hu)
PL (1) PL3294713T3 (hu)
PT (1) PT3294713T (hu)
RS (1) RS62016B1 (hu)
SI (1) SI3294713T1 (hu)
WO (1) WO2016185342A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3845526A1 (en) 2015-05-15 2021-07-07 Aurigene Discovery Technologies Limited Method for the preparation of tetrahydroquinolinone compounds having ror-gamma modulating activity
US10011566B2 (en) 2015-12-15 2018-07-03 Astrazeneca Ab Compounds
US10196350B2 (en) 2016-12-05 2019-02-05 Lead Pharma Holding B.V. ROR gamma (RORγ) modulators
CN108218845B (zh) * 2016-12-21 2022-11-29 江苏柯菲平医药股份有限公司 一类色满-6-磺酰胺RORγ调节剂及其用途
CN115586652A (zh) 2017-01-23 2023-01-10 奇跃公司 用于虚拟、增强或混合现实系统的目镜
CN107129488A (zh) * 2017-04-21 2017-09-05 湖南博奥德生物医药技术开发有限公司 一种艾乐替尼的制备方法
WO2018229155A1 (en) 2017-06-14 2018-12-20 Astrazeneca Ab 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN109111418B (zh) * 2017-06-23 2022-10-11 江苏柯菲平医药股份有限公司 一类2,3-二氢-1H-茚-4-磺酰胺RORγ调节剂及其用途
EP3581565A1 (en) * 2018-06-14 2019-12-18 Beijing Zhibo Bio-Medical Technology Co., Ltd. Phenyl benzyl ether derivative and preparation method and application thereof
CN109232416B (zh) * 2018-10-24 2021-09-24 福州大学 一种合成4-三氟甲基-2-吡喃酮/吡啶酮化合物的方法
AR117169A1 (es) 2018-11-28 2021-07-14 Bayer Ag (tio)amidas de piridazina como compuestos fungicidas
MX2021007515A (es) 2018-12-20 2021-08-05 Bayer Ag Compuestos de heterociclil piridazina como fungicidas.
US20220202811A1 (en) * 2019-02-20 2022-06-30 The Regents Of The University Of California Treatment for retinoic acid receptor-related orphan receptor Ɣ (rorƔ)-dependent cancers
CN109970631A (zh) * 2019-03-26 2019-07-05 上海吉奉生物科技有限公司 一种5-碘-2-吡啶乙酸的合成方法
WO2021136339A1 (zh) * 2019-12-31 2021-07-08 广东东阳光药业有限公司 具有双环结构的酰胺类化合物及其在药物中的应用
JP2023527036A (ja) 2020-05-27 2023-06-26 バイエル、アクチエンゲゼルシャフト 活性化合物の組合せ物
AU2021291371A1 (en) 2020-06-18 2023-02-02 Bayer Aktiengesellschaft Active compound combinations
CN112724089B (zh) * 2021-01-05 2022-08-26 烟台皓元生物医药科技有限公司 一种2-氨基-3-溴-6-氯吡嗪的合成工艺
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2256340T3 (es) 2000-12-06 2006-07-16 F. Hoffmann-La Roche Ag Activadores heteroaromaticos fusionados de la glucoquinasa.
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
CN1946703A (zh) * 2004-04-20 2007-04-11 特兰斯泰克制药公司 取代的噻唑和嘧啶衍生物作为黑素细胞皮质激素受体调节剂
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
WO2013029338A1 (en) * 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
EP2844259A4 (en) * 2012-04-30 2015-11-11 Anderson Gaweco MMR MODULATORS AND USES THEREOF
US9266827B2 (en) * 2012-05-08 2016-02-23 Merck Sharp & Dohme Corp. Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
WO2014125426A1 (en) * 2013-02-15 2014-08-21 Aurigene Discovery Technologies Limited Trisubstituted heterocyclic derivatives as ror gamma modulators
US9868748B2 (en) 2013-05-01 2018-01-16 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ROR- γ
EP3027616B1 (en) * 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Azaindole compounds as modulators of rorc
WO2015035032A1 (en) * 2013-09-05 2015-03-12 Boehringer Ingelheim International Gmbh Bicylic compounds as modulators of rorgamma
TN2016000224A1 (en) 2013-12-05 2017-10-06 Lead Pharma Holding Bv Ror gamma (rory) modulators
WO2015083130A1 (en) * 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
WO2015101928A1 (en) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
PE20161372A1 (es) 2014-02-03 2017-01-08 Vitae Pharmaceuticals Inc Inhibidores de dihidropirrolopiridina de ror-gamma
WO2015145371A1 (en) 2014-03-27 2015-10-01 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
WO2015160654A1 (en) 2014-04-14 2015-10-22 Boehringer Ingelheim International Gmbh Compounds as modulators of ror gamma
CA2940264A1 (en) 2014-04-16 2015-10-22 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
UA118989C2 (uk) 2014-10-14 2019-04-10 Вітае Фармасьютікалс, Інк. Дигідропіролопіридинові інгібітори ror-гамма
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
EP3845526A1 (en) 2015-05-15 2021-07-07 Aurigene Discovery Technologies Limited Method for the preparation of tetrahydroquinolinone compounds having ror-gamma modulating activity
WO2016193894A1 (en) 2015-05-29 2016-12-08 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using ror- gamma inhibitors
WO2017010399A1 (ja) 2015-07-10 2017-01-19 塩野義製薬株式会社 RORγt阻害作用を有する化合物およびそれらを含有する医薬組成物
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ROR-γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma

Also Published As

Publication number Publication date
WO2016185342A1 (en) 2016-11-24
ES2868175T3 (es) 2021-10-21
JP2018515531A (ja) 2018-06-14
AU2021200330A1 (en) 2021-03-18
RS62016B1 (sr) 2021-07-30
HUE054009T4 (hu) 2021-06-28
HK1255229A1 (zh) 2019-08-09
IL255522A (en) 2018-01-31
BR112017024517A2 (pt) 2018-07-24
KR20180029971A (ko) 2018-03-21
PL3294713T4 (pl) 2021-07-26
AU2021200330B2 (en) 2022-07-28
US11229636B2 (en) 2022-01-25
SI3294713T1 (sl) 2021-08-31
EA201792515A1 (ru) 2018-03-30
EP3845526A1 (en) 2021-07-07
JP2020117514A (ja) 2020-08-06
CN108026045B (zh) 2021-04-27
US20220125780A1 (en) 2022-04-28
DK3294713T3 (da) 2021-05-10
AU2016262969C1 (en) 2022-02-24
CN113121497A (zh) 2021-07-16
LT3294713T (lt) 2021-06-10
CY1124129T1 (el) 2022-05-27
AU2016262969B2 (en) 2020-10-22
HRP20210745T1 (hr) 2021-06-25
EP3294713A4 (en) 2018-10-24
EP3294713B1 (en) 2021-02-17
PH12017502052A1 (en) 2018-04-30
PT3294713T (pt) 2021-05-24
CU20170144A7 (es) 2018-04-03
IL290153A (en) 2022-03-01
CA2985547C (en) 2024-02-20
KR102702236B1 (ko) 2024-09-04
MY189194A (en) 2022-01-31
IL255522B (en) 2022-03-01
JP6684516B2 (ja) 2020-04-22
CN108026045A (zh) 2018-05-11
CU24487B1 (es) 2020-11-30
US20180200247A1 (en) 2018-07-19
US20200113892A1 (en) 2020-04-16
CA2985547A1 (en) 2016-11-24
MX2021009561A (es) 2022-08-01
MX2017014621A (es) 2018-06-28
PL3294713T3 (pl) 2021-07-26
EA036679B1 (ru) 2020-12-08
EP3294713A1 (en) 2018-03-21
JP6982376B2 (ja) 2021-12-17
AU2016262969A1 (en) 2018-01-04
US20210113551A9 (en) 2021-04-22
DK3294713T5 (da) 2021-05-31

Similar Documents

Publication Publication Date Title
IL290153A (en) Tetrahydroquinolinone compounds are installed such as gamma modulators
IL263878B (en) Compounds as gamma ror modulators
HK1254692A1 (zh) 作為RORγ調節劑的新型化合物
IL256038A (en) Realtors ror gamma
IL256034B (en) brokers ror gamma
IL256036B (en) brokers ror gamma
IL256037B (en) brokers ror gamma
IL256039B (en) brokers ror gamma
SG11201604755QA (en) Substituted dihydro-benzimidazole compounds as ror gamma modulators
HK1257756A1 (zh) 作為RORγ調節劑的新型碳環化合物